Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.93% as of July 1, 2025, with notable gains from stocks such as Rongchang Biopharmaceutical (688331) up 7.21% and Shanghai Yizhong (688091) up 3.61% [1] - Starting July 1, 2025, a new policy mandates that all drug sales must include a verification code for medical insurance reimbursement, with full traceability of drug codes required by January 1, 2026, which is expected to enhance drug circulation regulation and impact the entire pharmaceutical industry chain [1] - The current bull market in innovative drugs is driven by the improvement of China's pharmaceutical innovation capabilities, with a trend towards international collaboration in new drug development expected to enhance profitability and market potential for Chinese pharmaceutical companies [2] Group 2 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [3] - The Sci-Tech Biopharmaceutical ETF closely tracks the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in various biopharmaceutical sectors [2]

证券代码：688016 证券简称：心脉医疗 公告编号：2025-027 上海微创心脉医疗科技（集团）股份有限公司 关于自愿披露获得第二十五届中国专利金奖的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《国家知识产权局关于第二十五届中国专利奖授奖的决定》（国知发运 字〔2025〕20 号），上海微创心脉医疗科技（集团）股份有限公司（以下简称 "公司"或"心脉医疗"）成功获得第二十五届中国专利金奖。 中国专利奖由国家知识产权局与世界知识产权组织共同评选，旨在引导和推 进知识产权工作对供给侧结构性改革、创新型国家建设、经济高质量发展发挥重 要作用；鼓励和表彰专利权人和发明人（设计人）对技术（设计）创新及经济社 会发展作出的突出贡献。根据《中国专利奖评奖办法》规定，中国专利奖参评项 目采用推荐方式，由地方知识产权局、国务院有关部门和单位知识产权工作管理 机构、全国性行业协会、中国科学院院士和中国工程院院士等根据当年评选通知 要求择优推荐。第二十五届中国专利奖共授奖中国专利金奖 30 项，中国外观设 计金奖 10 项，中 ...

Group 1 - Company has been awarded the 25th China Patent Gold Award, recognizing its contributions to innovation and intellectual property in the medical device sector [1] - The China Patent Award aims to promote structural reform on the supply side and high-quality economic development through the encouragement of patent holders and inventors [1] - A total of 30 China Patent Gold Awards, 10 China Design Gold Awards, 60 China Patent Silver Awards, 15 China Design Silver Awards, 607 China Patent Excellence Awards, and 47 China Design Excellence Awards were granted in this edition [1] Group 2 - Since its establishment, the company has focused on interventional medical devices for the aorta and peripheral blood vessels, becoming a leading enterprise in this field in China [2] - As of December 31, 2024, the company has submitted a total of 724 patent applications, with 242 patents granted both domestically and internationally [2] - The granted patents include 155 domestic patents (74 invention patents, 77 utility model patents, and 4 design patents) and 87 international patents (all invention patents) [2]

证券代码：688016 证券简称：心脉医疗 公告编号：2025-026 上海微创心脉医疗科技（集团）股份有限公司 关于以集中竞价交易方式第二期回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日（第二期） | 2024/10/30 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限（第二期） | 年 月 2024 10 28 10 | 日~2025 | 年 | 月 | 27 | 日 | | 预计回购金额（第二期） | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | 累计已回购股数（第二期） | □为维护公司价值及股东权益 905,989股 | | | | | | | 累计已回购股数占总股本比例 | 0.74% | | | | | | | （第二期） | | | | | ...

Trading Information Summary - On May 30, 2025, the stock price of Xinmai Medical (688016) closed at 87.94 yuan, down 0.07%, with a turnover rate of 1.06%, trading volume of 13,100 shares, and a transaction amount of 116 million yuan [1] - The capital flow on the same day showed a net inflow of 8.1975 million yuan from main funds, while retail funds experienced a net outflow of 4.7138 million yuan and speculative funds saw a net outflow of 3.4837 million yuan [1][4] Company Announcements Summary - Xinmai Medical adjusted the total cash dividend for the 2024 profit distribution to 42,444,159.80 yuan (including tax), maintaining a cash dividend of 3.5 yuan (including tax) per 10 shares [1][2][4] - The record date for the 2024 annual equity distribution is set for June 5, 2025, with the ex-dividend date and cash dividend payment date on June 6, 2025 [2][4] - The company has adjusted the upper limit of the repurchase price for the second phase of the share buyback plan from 178.35 yuan per share to 178.01 yuan per share, effective from June 6, 2025 [2][4] - China International Capital Corporation conducted a review of the differentiated dividend distribution matters, confirming that shares repurchased into the company's special account do not have profit distribution rights, leading to the implementation of differentiated equity distribution [2]

Group 1 - The stock price of Xinmai Medical (688016) closed at 87.94 yuan on May 30, 2025, up 1.75% from the previous week [1] - The company's total market capitalization is 10.84 billion yuan, ranking 27th out of 126 in the medical device sector and 1432nd out of 5146 in the A-share market [1] - The highest intraday price reached 88.98 yuan, while the lowest was 85.8 yuan during the week [1] Group 2 - Xinmai Medical adjusted the total cash dividend for the 2024 profit distribution to 42,444,159.80 yuan (including tax), maintaining a cash dividend of 3.5 yuan per 10 shares [1][3] - The record date for the cash dividend is June 5, 2025, with the ex-dividend date and payment date set for June 6, 2025 [1][3] - The actual number of shares participating in the distribution is 121,269,028 [1] Group 3 - The company revised the upper limit of the second phase of its share repurchase plan from 178.35 yuan per share to 178.01 yuan per share, effective from June 6, 2025 [2] - The total repurchase fund limit is set at 200 million yuan, with an estimated repurchase quantity of 1,123,532 shares, accounting for approximately 0.91% of the total share capital [2] - China International Capital Corporation conducted a review of the differentiated dividend distribution and confirmed its compliance with relevant laws and regulations [2]

Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2] - The main products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2] - The company has received several awards, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2] Financial Performance - For Q1 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23% [2] - The net profit for the same period was 130 million yuan, down 29.66% year-on-year, with a gross profit margin of 69.61% [2] Market Position - As of May 29, the company's stock closed at 88.0 yuan, with a rolling price-to-earnings (PE) ratio of 24.24 [1] - The average PE ratio in the medical device industry is 49.64, with a median of 36.36, placing the company at the 52nd position in the industry ranking [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 18,176, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 差异化分红事项的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为上海微 创心脉医疗科技（集团）股份有限公司（以下简称"公司"、"心脉医疗"）向特定对 象发行股票项目的保荐机构，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号——回购股 份》等相关法律法规和规范性文件的要求，对心脉医疗2024年年度利润分配涉及的差异 化分红事项（以下简称"本次差异化分红"）进行了审慎核查，具体情况如下： 一、本次差异化分红的原因 2024 年 7 月 23 日，公司召开第二届董事会第二十九次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海证券交易 所系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股）股票，并在未 来适宜时机全部用于股权激励或员工持股计划。公司本次回购价格不超过人民币 130.00 元/股（含），回购资金总额不低于人民币 6,000.00 万元（含），不超过人民币 10,000.00 ...

公司拟以实施 2024 年年度权益分派股权登记日的总股本（扣减回购专用证 券账户的股份）为基数，向全体股东每 10 股派发现金红利人民币 3.5 元（含税）。 截至 2025 年 2 月 28 日，公司总股本为 123,262,117 股，其中，公司回购证券专 用账户的股份数量为 1,952,089 股，以此扣减回购专用账户的股份数量后公司股 现金分红总额调整情况：维持每10股派发现金红利3.5元（含税）不变， 现金分红总额由42,458,509.80元（含税）调整为42,444,159.80元（含税）。 调整原因：自2025年3月1日起至本公告披露日，公司通过上海证券交易 所交易系统以集中竞价交易方式回购公司股份41,000股。因公司回购专 用证券账户中股份总数发生变动，实际参与本次利润分配的股份总数调 整为121,269,028股。根据公司2024年度利润分配方案，维持应分配每股 比例不变，相应调整分配总额。 份数量为 121,310,028 股，以此计算公司拟派发现金红利总额为 42,458,509.80 元 （含税）。公司不进行资本公积金转增股本，不送红股。 如在利润分配预案披露 日至实施权益分派股权 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-025 上海微创心脉医疗科技（集团）股份有限公司 关于实施 2024 年度利润分配方案后调整第二期股份 回购方案回购价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 回购股份的基本情况 2024 年 10 月 28 日，上海微创心脉医疗科技（集团）股份有限公司（以下 简称"公司"）召开第三届董事会第二次会议，审议通过了《关于以集中竞价交 易方式第二期回购公司股份方案的议案》,同意公司以自有资金和/或自筹资金通 过上海证券交易所系统以集中竞价交易方式回购公司已发行的部分人民币普通 股（A 股）股票，并在未来适宜时机全部用于股权激励或员工持股计划。公司本 次回购价格不超过人民币 180 元/股（含），回购资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的实施期限自董事会审 议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2024 年 10 月 30 日刊登在上海证券交易 ...